Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition.

Cigarette smoking causes nearly one in every five deaths in the United States. The development of a specific inhibitor of cytochrome P450 2A6 (CYP2A6), the major nicotine-metabolizing enzyme in humans, which could be prescribed for the cessation of cigarette smoking, has been undertaken. To further refine the structure activity relationship of CYP2A6, previously synthesized 3-alkynyl and 3-heteroaromatic substituted pyridine methanamines were used as lead compounds. Isosteric pyridine replacement and appendage of all available positions around the pyridine ring with a methyl group was performed to identify a modification that would increase CYP2A6 inhibition potency, which led to 4g (IC50 = 0.055 mM) as a primary analogue. Potent compounds were evaluated for CYP selectivity, human liver microsomal half-life, and compliance with the rules of five. Top compounds (i.e., 6i, IC50 = 0.017 mM, >120 min half-life) are poised for further development as treatments for smoking and tobacco use cessation.

• Publication year

  2018

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2018-07-11

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/acs.jmedchem.8b00084PMID 29995408PMCID PMC6309628
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Quitting Smoking Among Adults - United States, 2000-2015.

  2017cited by this paper
• Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial.

  2016cited by this paper
• Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis

  2015cited by this paper
• Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice.

  2014cited by this paper
• The Health consequences of smoking—50 years of progress : a report of the Surgeon General

  2014cited by this paper
• Quitting smoking among adults--United States, 2001-2010.

  2011cited by this paper
• Suicidal Behavior and Depression in Smoking Cessation Treatments

  2011cited by this paper
• Thoughts and Acts of Aggression/Violence Toward Others Reported in Association with Varenicline

  2010cited by this paper
• Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization.

  2006cited by this paper
• Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance

  2006cited by this paper
• Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

  2006cited by this paper
• Efficacy of Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial

  2006cited by this paper
• Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen

  2005cited by this paper
• 5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.

  2005cited by this paper
• Actual causes of death in the United States, 2000.

  2004cited by this paper
• Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6.

  2004cited by this paper
• The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo.

  2003cited by this paper
• Association of CYP2A6 Gene Deletion with Cigarette Smoking Status in Japanese Adults

  2003cited by this paper
• Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking

  2000cited by this paper
• Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking.

  2000cited by this paper
• Nicotine metabolism defect reduces smoking

  1998cited by this paper
• Actual causes of death in the United States.

  1994cited by this paper
• Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N'-oxide.

  1992cited by this paper
• Nicotine's role in smoking: an analysis of nicotine regulation.

  1983cited by this paper

• Inhibition of CYP2A6-mediated nicotine metabolism: A potential strategy for smoking cessation therapy.

  2025cites this paper
• Synthesis and biological evaluation of coumarin derivatives as selective CYP2A6 inhibitors.

  2023cites this paper
• Propargylamine: an important moiety in drug discovery.

  2023cites this paper
• Identification of CYP 2A6 inhibitors in an effort to mitigate the harmful effects of the phytochemical nicotine

  2021cites this paper
• Crystal structure, Hirshfeld surface analysis, and Molecular Dynamics Simulations of two isostructural N-propargyl-4-(2-oxopyrrolidin-1-yl)-1,2,3,4-tetrahydroquinolines

  2021cites this paper
• Thermodynamic properties of 5-(2-nitrophenyl) furan-2-carbaldehyde and it’s derivatives in a condensed state

  2020cites this paper
• Inhibition of human cytochrome P450 2A6 by 7-hydroxycoumarin analogues: Analysis of the structure-activity relationship and isoform selectivity.

  2019cites this paper
• Human Self-Domestication and the Extended Evolutionary Synthesis of Addiction: How Humans Evolved a Unique Vulnerability.

  2019cites this paper
• The Novel CYP2A6 Inhibitor, DLCI-1, Decreases Nicotine Self-Administration in Mice

  2019cites this paper
• Thermodynamic Properties of 2-Methyl-5-arylfuran-3 Carboxylic Acids Chlorine Derivatives in Organic Solvents

  2019cites this paper
• УДК 547

  2018influential citation